Arvind Kumar Shukla

Dr. Arvind Kumar Shukla

School of Biomedical Convergence Engineering, Pusan National University, Busan, Republic of Korea
orcid
He studies the cancer stem cell biology, 3D bioprinting for ...

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
GMGabriella Mirone
Gabriella Mirone
SPStefania Perna
Stefania Perna
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
GMGabriella Marfe
Gabriella Marfe

20 January 2022 in Micromachines
Verified
Journal Article
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Ge GaoGe Gao
Ge Gao
Byoung Soo KimByoung Soo Kim
Byoung Soo Kim
Induced pluripotent stem cells (iPSCs) are essentially produced by the genetic reprogramming of adult cells. Moreover, iPSC technology prevents the genetic manipulation of embryos. Hence, with the ensured element of safety, they rarely cause ethical concerns when utilized in tissue engineering. Several cumulative outcomes have demonstrated the functional superiority and potency of iPSCs in advanced regenerative medicine. Recently, an emerging trend in 3D bioprinting technology has been a more comprehensive approach to iPSC-based tissue engineering. The principal aim of this review is to provide an understanding of the applications of 3D bioprinting in iPSC-based tissue engineering. This review discusses the generation of iPSCs based on their distinct purpose, divided into two categories: (1) undifferentiated iPSCs applied with 3D bioprinting; (2) differentiated iPSCs applied with 3D bioprinting. Their significant potential is analyzed. Lastly, various applications for engineering tissues and organs have been introduced and discussed in detail.

Verified
Journal Article
Open access
PDF file
RMRAJ MONGRE
RAJ MONGRE
CMChandra Mishra
Chandra Mishra
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
APAmresh Prakash
Amresh Prakash
SJSamil Jung
Samil Jung
MLMyeong-Sok Lee
Myeong-Sok Lee
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.

10 March 2021 in Materials
Verified
Journal Article
Open access
PDF file
CAChaima Amri
Chaima Amri
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Jin-Ho LeeJin-Ho Lee
Jin-Ho Lee
The effectiveness of cancer treatment strongly depends on the early detection of the disease. Currently, the most common diagnostic method, tissue biopsy, takes time and can be damaging to the patient. Circulating cancer biomarkers such as circulating tumor DNA, micro-RNA (miRNA), tumor proteins, exosomes, and circulating tumor cells have repeatedly demonstrated their viability as targets for minimally invasive cancer detection through liquid biopsies. However, among other things, achieving a great sensitivity of detection is still challenging due to the very low concentration of biomarkers in fluid samples. This review will discuss how the recent advances in nanoparticle-based biosensors are overcoming these practical difficulties. This report will be focusing mainly on optical transduction mechanisms of metal nanoparticles (M-NPs), quantum dots (QDs), and upconversion nanoparticles (UCNPs).

5 October 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
GMGabriella Marfe
Gabriella Marfe
SPStefania Perna
Stefania Perna
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
At the end of 2019, a new disease recognized such as severe acute respiratory syndrome (SARS), was reported in Wuhan, China. This disease was caused by an unknown SARS coronavirus 2 (SARS‑CoV‑2); a virus is characterized by high infectivity among humans. In some cases, this disease can be asymptomatic, while in other cases can induce flu‑like symptoms or acute respiratory distress syndrome, pneumonia and death. For this reason, the World Health Organization and Public Health Emergency of International Concern declared a pandemic status in January 2020. Currently, numerous countries have been involved in the development of effective vaccines to protect humans against SARS‑CoV‑2 infection. The present review will discuss the four vaccines, AZD1222 (AstraZeneca or Vaxzevria), Janssen (Ad26.COV2.S), Moderna/mRNA‑1273 and BioNTech/Fosun/Pfizer BNT162b1, that are currently in use worldwide to understand their efficacy, but also evaluate the difficulties and challenges of vaccine development. Although several questions should be addressed regarding these vaccines, the current review will examine the viral elements used in the coronavirus‑19 vaccine that can play a crucial role in inducing a strong immune response, as well as the different adverse effects that they can cause to individuals.

26 March 2015 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GMGabriella Marfe
Gabriella Marfe
GMGiovanna Mirone
Giovanna Mirone
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
CSCarla Stefano
Carla Stefano
Sphingosine kinases (Sphk1 and 2) regulate the prodution of sphingosine-1-phosphate (S1P), that is key molecule in cancer development. SphK1, which is commonly overexpressed in malignant tumours, significantly contributes to the pathogenesis of various types of cancer as well as to resistance to different Tyrosine Kinase inibitors (TKIs). Even, SphK2 may promote apoptosis and inhibit cell growth but its role has not yet been fully understood in pathologic conditions. Different growth factorsinduced activation of receptor tyrosine kinases (RTKs) results in production of Sphk1 which catalyzes the phosphorylation of sphingosine. Such enzyme, in turn, is involved in many cellular processes by its five receptors. These are able to transactivate RTKs through amplification of a positive-feedback signaling loop. In conclusion, development of pharmacological inhibitors of SphK1 has been limited by the lack of completely understanding of the enzymatic activation mechanisms of SphK1.